Kunpeng Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kunpeng Wu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Dan Tian
4 shared publicationsHai-Jing Yang
3 shared publicationsHong-Cheng Yang
3 shared publications- Lei Chen
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
3 shared publications Qing-Qing Li
3 shared publicationsXie Zhu
3 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by Elsevier in SSRN Electronic Journal
Defining the Role of Locoregional Radiotherapy for De Novo Metastatic Nasopharyngeal Carcinoma in the Immunotherapy Era: A Systematic Review and Meta-Analysis
Background: Nasopharyngeal carcinoma (NPC), endemic to Southern China and Southeast Asia, presents significant clinical challenges. Immune checkpoint inhibitors (ICIs) have transformed NPC treatment but carry risks of immune-related adverse events (irAEs). Existing meta-analyses lack NPC-specific data, hindering targeted safety guidance.Methods: This systematic review and meta-analysis, registered with PROSPERO (CRD420251003062), followed PRISMA guidelines. We searched PubMed, Embase, and Web of Science up to March 31, 2025, including all registered clinical trials of ICIs in NPC patients reporting irAEs. Meta-analysis was employed to calculate all grade and ≥3 grade irAE incidence rates. Pooled analysis was applied to delineate the cumulative number of cases for all kinds of irAE and the causes of death attributed to irAEs in patients with NPC.Findings: A total of 27 clinical trials were included in the meta-analysis. The pooled incidence of all-grade irAEs in 2296 patients was 69.1% (95% CI: 50.4%-80.7%), and that of grade 3 or higher irAEs in 2459 patients was 8.1% (95% CI: 6.1%-10.6%). Subgroup analyses revealed that there were no significant differences in the incidence of irAEs based on disease stages, lines of treatment, and combination treatment strategies. The main types of all-grade irAEs with an incidence rate greater than 1% are as follows: hypothyroidism (22.4%), rash (10.7%), pruritus (3.6%), increased aspartate aminotransferase (1.9%), increased alanine aminotransferase (1.8%), fatigue (1.6%), anemia (1.6%), pneumonia (1.5%), and hyperthyroidism (1.0%). A total of 17 patients died due to irAEs. Among these, sepsis was the most common cause of death, followed by pneumonitis.Interpretation: This meta-analysis provides a comprehensive overview of irAEs in NPC patients treated with ICIs. These NPC-specific data emphasize the importance of vigilant monitoring for endocrine, cutaneous, and severe pulmonary or infectious complications to balance the efficacy and safety of ICIs.
- 21 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDefining the Role of Locoregional Radiotherapy for De Novo Metastatic Nasopharyngeal Carcinoma in the Immunotherapy Era: A Systematic Review and Meta-Analysis
Background: Nasopharyngeal carcinoma (NPC), endemic to Southern China and Southeast Asia, presents significant clinical challenges. Immune checkpoint inhibitors (ICIs) have transformed NPC treatment but carry risks of immune-related adverse events (irAEs). Existing meta-analyses lack NPC-specific data, hindering targeted safety guidance.Methods: This systematic review and meta-analysis, registered with PROSPERO (CRD420251003062), followed PRISMA guidelines. We searched PubMed, Embase, and Web of Science up to March 31, 2025, including all registered clinical trials of ICIs in NPC patients reporting irAEs. Meta-analysis was employed to calculate all grade and ≥3 grade irAE incidence rates. Pooled analysis was applied to delineate the cumulative number of cases for all kinds of irAE and the causes of death attributed to irAEs in patients with NPC.Findings: A total of 27 clinical trials were included in the meta-analysis. The pooled incidence of all-grade irAEs in 2296 patients was 69.1% (95% CI: 50.4%-80.7%), and that of grade 3 or higher irAEs in 2459 patients was 8.1% (95% CI: 6.1%-10.6%). Subgroup analyses revealed that there were no significant differences in the incidence of irAEs based on disease stages, lines of treatment, and combination treatment strategies. The main types of all-grade irAEs with an incidence rate greater than 1% are as follows: hypothyroidism (22.4%), rash (10.7%), pruritus (3.6%), increased aspartate aminotransferase (1.9%), increased alanine aminotransferase (1.8%), fatigue (1.6%), anemia (1.6%), pneumonia (1.5%), and hyperthyroidism (1.0%). A total of 17 patients died due to irAEs. Among these, sepsis was the most common cause of death, followed by pneumonitis.Interpretation: This meta-analysis provides a comprehensive overview of irAEs in NPC patients treated with ICIs. These NPC-specific data emphasize the importance of vigilant monitoring for endocrine, cutaneous, and severe pulmonary or infectious complications to balance the efficacy and safety of ICIs.
- Open Access
- 16 March 2026
- Published by Elsevier in SSRN Electronic Journal
Tumor Regression Dynamics and Implications for Radiotherapy Replanning and PD-1 Blockade in Nasopharyngeal Carcinoma: A Retrospective Cohort Study
Purpose: To investigate the optimal replanning timing for adaptive radiotherapy and the role of programmed cell death protein-1 (PD-1) blockade in nasopharyngeal carcinoma (NPC).Patients and Methods: In this retrospective, longitudinal time-series, cohort study, patients with NPC underwent intensity-modulated radiotherapy with daily or weekly cone beam computed tomography (CBCT) in China between 2020 and 2023. CBCT image-based delineations were conducted to evaluate dynamic changes of the primary tumor, lymph nodes, and parotid glands. Parotid function was assessed via the European Organization for Research and Treatment of Cancer questionnaire. Between-group comparisons were performed using Two-way Repeated-Measures ANCOVA. Kaplan-Meier analysis and Cox regression were used to compare survival outcomes.Results: Analysis of 404 eligible patients (31·8% women) revealed two distinct patterns of rapid and slow regression for primary tumors (25,580 images; least‑squares mean difference, -0·929cm2; p<0·001) and lymph nodes (4,041 images; least‑squares mean difference, -0·083cm2; p<0·001). Parotid glands were more susceptible to shrinkage in the rapid regression group than in the slow regression group, with an increased risk of dry mouth (p=0·033) and sticky saliva (p=0·029). The primary tumor showed sustained significant reduction in the rapid regression group until the 21st fractions, before the mean parotid dose reached the restricted threshold of 25 Gy. Concurrent PD-1 blockade correlated with slower regression of the primary tumor (p=0·035) and lymph nodes (p=0·005). Patients with primary tumor regression by the 6th fraction had significantly improved event-free survival (HR, 0·37; 95% CI, 0·15 to 0·95; p=0·031) and overall survival (HR, 0·24; 95% CI, 0·05 to 0·98; p=0·043).Conclusions: The 21st fraction was proposed to trigger radiotherapy replanning for rapidly regressing NPC. Compared with concurrent chemoradiotherapy, additional PD-1 blockade was associated with poorer tumor regression.
- 16 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTumor Regression Dynamics and Implications for Radiotherapy Replanning and PD-1 Blockade in Nasopharyngeal Carcinoma: A Retrospective Cohort Study
Purpose: To investigate the optimal replanning timing for adaptive radiotherapy and the role of programmed cell death protein-1 (PD-1) blockade in nasopharyngeal carcinoma (NPC).Patients and Methods: In this retrospective, longitudinal time-series, cohort study, patients with NPC underwent intensity-modulated radiotherapy with daily or weekly cone beam computed tomography (CBCT) in China between 2020 and 2023. CBCT image-based delineations were conducted to evaluate dynamic changes of the primary tumor, lymph nodes, and parotid glands. Parotid function was assessed via the European Organization for Research and Treatment of Cancer questionnaire. Between-group comparisons were performed using Two-way Repeated-Measures ANCOVA. Kaplan-Meier analysis and Cox regression were used to compare survival outcomes.Results: Analysis of 404 eligible patients (31·8% women) revealed two distinct patterns of rapid and slow regression for primary tumors (25,580 images; least‑squares mean difference, -0·929cm2; p<0·001) and lymph nodes (4,041 images; least‑squares mean difference, -0·083cm2; p<0·001). Parotid glands were more susceptible to shrinkage in the rapid regression group than in the slow regression group, with an increased risk of dry mouth (p=0·033) and sticky saliva (p=0·029). The primary tumor showed sustained significant reduction in the rapid regression group until the 21st fractions, before the mean parotid dose reached the restricted threshold of 25 Gy. Concurrent PD-1 blockade correlated with slower regression of the primary tumor (p=0·035) and lymph nodes (p=0·005). Patients with primary tumor regression by the 6th fraction had significantly improved event-free survival (HR, 0·37; 95% CI, 0·15 to 0·95; p=0·031) and overall survival (HR, 0·24; 95% CI, 0·05 to 0·98; p=0·043).Conclusions: The 21st fraction was proposed to trigger radiotherapy replanning for rapidly regressing NPC. Compared with concurrent chemoradiotherapy, additional PD-1 blockade was associated with poorer tumor regression.
- 5 September 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 133 (10) , 1518-1525
Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis
Background Locally advanced nasopharyngeal carcinoma (LA-NPC) has a heterogeneous prognosis, with approximately one-fourth of patients experiencing poor outcomes. Studies have explored the application of induction chemoimmunotherapy followed by chemoradiotherapy, but its efficacy was controversial. Methods The protocol was registered in the Prospective Register of Systematic Reviews (PROSPERO, CRD42024619387). The primary outcome measures were objective response rate (ORR), complete response rate (CRR), and the incidence of treatment-related adverse events (TRAEs). Meta-analysis was performed using Cochrane Collaboration Review Manager 5.4.1 and Meta-Analyst Beta 3.13 statistical software. Results The meta-analysis involving 1680 patients with LA-NPC from 7 studies showed that the induction chemoimmunotherapy group had significantly better ORR (odds ratio[OR] = 2.03, 95% confidence interval [CI]:1.44–2.86, P < 0.01), and CRR (OR = 2.61, 95% CI:1.55–4.38, P < 0.01) than the induction chemotherapy group. The pooled ORR and CRR of induction chemoimmunotherapy were 92.7% (95% CI: 90.7–94.7%) and 24.3% (95% CI: 15.2–33.6%), respectively. There was no significant difference of TRAEs between induction chemotherapy group and induction chemoimmunotherapy group (OR = 1.13; 95% CI: 0.92–1.39, P = 0.23). Conclusions Induction chemoimmunotherapy could be a promising induction treatment option for LA-NPC patients, improving ORR and CRR with an acceptable safety profile. However, due to limitations in this meta-analysis, further large-scale, well-designed clinical trials are required to validate these results and optimise treatment strategies.
- 5 September 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 133 (10) , 1518-1525
Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis
Background Locally advanced nasopharyngeal carcinoma (LA-NPC) has a heterogeneous prognosis, with approximately one-fourth of patients experiencing poor outcomes. Studies have explored the application of induction chemoimmunotherapy followed by chemoradiotherapy, but its efficacy was controversial. Methods The protocol was registered in the Prospective Register of Systematic Reviews (PROSPERO, CRD42024619387). The primary outcome measures were objective response rate (ORR), complete response rate (CRR), and the incidence of treatment-related adverse events (TRAEs). Meta-analysis was performed using Cochrane Collaboration Review Manager 5.4.1 and Meta-Analyst Beta 3.13 statistical software. Results The meta-analysis involving 1680 patients with LA-NPC from 7 studies showed that the induction chemoimmunotherapy group had significantly better ORR (odds ratio[OR] = 2.03, 95% confidence interval [CI]:1.44–2.86, P < 0.01), and CRR (OR = 2.61, 95% CI:1.55–4.38, P < 0.01) than the induction chemotherapy group. The pooled ORR and CRR of induction chemoimmunotherapy were 92.7% (95% CI: 90.7–94.7%) and 24.3% (95% CI: 15.2–33.6%), respectively. There was no significant difference of TRAEs between induction chemotherapy group and induction chemoimmunotherapy group (OR = 1.13; 95% CI: 0.92–1.39, P = 0.23). Conclusions Induction chemoimmunotherapy could be a promising induction treatment option for LA-NPC patients, improving ORR and CRR with an acceptable safety profile. However, due to limitations in this meta-analysis, further large-scale, well-designed clinical trials are required to validate these results and optimise treatment strategies.
- 7 January 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (6) , 9831-9838
NEAT1 is a potential prognostic biomarker for patients with nasopharyngeal carcinoma
Nuclear paraspeckle assembly transcript 1 (NEAT1) has been found to be dysregulated and associated with clinical progression in various human cancers. The clinical and prognostic value of NEAT1 in nasopharyngeal carcinoma (NPC) was still controversial. The aim of our study was to provide more sufficient evidence that NEAT1 expression is correlated with overall survival in patients with NPC. NEAT1 expression was detected in NPC tissue samples, and the relationship between NEAT1 expression and clinical parameters, including prognosis, was analyzed. The meta‐analysis was performed to further assess the prognostic significance of NEAT1 expression in patients with NPC. In our study, we found that the levels of NEAT1 expression were increased in NPC clinical tissue specimens, and associated with advanced M classification and clinical stages. Moreover, the Kaplan‐Meier analysis suggested that the levels of NEAT1 expression were negatively associated with the overall survival of patients with NPC. Furthermore, univariate and multivariate Cox regression analyses showed that NEAT1 high‐expression was an independent unfavorable prognostic factor in patients with NPC. Finally, we conducted a meta‐analysis including 297 patients with NPC from the three studies, and found the pooled HR (95% confidence interval [CI]) was 1.64 (95% CI: 0.68‐3.93) for the random effects model and 2.04 (95% CI: 1.42‐2.95) for the fixed effect model. In conclusion, NEAT1 is a potential prognostic biomarker for NPC, but more studies are needed to further verify the prognostic value of NEAT1 in patients with NPC.
- 7 January 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (6) , 9831-9838
NEAT1 is a potential prognostic biomarker for patients with nasopharyngeal carcinoma
Nuclear paraspeckle assembly transcript 1 (NEAT1) has been found to be dysregulated and associated with clinical progression in various human cancers. The clinical and prognostic value of NEAT1 in nasopharyngeal carcinoma (NPC) was still controversial. The aim of our study was to provide more sufficient evidence that NEAT1 expression is correlated with overall survival in patients with NPC. NEAT1 expression was detected in NPC tissue samples, and the relationship between NEAT1 expression and clinical parameters, including prognosis, was analyzed. The meta‐analysis was performed to further assess the prognostic significance of NEAT1 expression in patients with NPC. In our study, we found that the levels of NEAT1 expression were increased in NPC clinical tissue specimens, and associated with advanced M classification and clinical stages. Moreover, the Kaplan‐Meier analysis suggested that the levels of NEAT1 expression were negatively associated with the overall survival of patients with NPC. Furthermore, univariate and multivariate Cox regression analyses showed that NEAT1 high‐expression was an independent unfavorable prognostic factor in patients with NPC. Finally, we conducted a meta‐analysis including 297 patients with NPC from the three studies, and found the pooled HR (95% confidence interval [CI]) was 1.64 (95% CI: 0.68‐3.93) for the random effects model and 2.04 (95% CI: 1.42‐2.95) for the fixed effect model. In conclusion, NEAT1 is a potential prognostic biomarker for NPC, but more studies are needed to further verify the prognostic value of NEAT1 in patients with NPC.